Next Article in Journal
A Difficult Case of Hodgkin Lymphoma with Differential Diagnosis of Tuberculosis and Sarcoidosis
Previous Article in Journal
Angioimmunoblastic T-Cell Lymphoma Presenting with an Acute Serologic Epstein-Barr Virus Profile
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Hematology Reports
Volume 7
Issue 2
10.4081/hr.2015.5812
hematolrep-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Hematology Reports is published by MDPI from Volume 14 Issue 1 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with PAGEPress.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Favorable Event Free-Survival of High-Dose Chemotherapy followed by Autologous Hematopoietic Stem Cell Transplantation for Higher Risk Diffuse Large B-Cell Lymphoma in First Complete Remission

by
Hiroto Kaneko
1,*,
Yasuhiko Tsutsumi
1,
Takahiro Fujino
1,
Saeko Kuwahara
1,
Muneo Ohshiro
1,
Toshiki Iwai
1,
Junya Kuroda
2,
Shouhei Yokota
2,
Shigeo Horiike
2 and
Masafumi Taniwaki
2
1
Department of Hematology, Japanese Red Cross Kyoto Daiichi Hospital, 15-749 Honmachi, Higashiyama-ku, Kyoto 605-0981, Japan
2
Department of Hematology/Oncology, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan
*
Author to whom correspondence should be addressed.
Hematol. Rep. 2015, 7(2), 5812; https://doi.org/10.4081/hr.2015.5812
Submission received: 14 January 2015 / Revised: 15 March 2015 / Accepted: 16 April 2015 / Published: 8 June 2015

Abstract

High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) has been applied to patients with diffuse large B-cell lymphoma (DLBCL); it is well established that ASCT shows significant survival benefits for chemosensitive relapse. However, half of relapsed patients are resistant to salvage chemotherapy, indicating that they are not suitable for ASCT. We retrospectively analyzed the clinical records of 47 patients with DLBCL classified as high or high-intermediate (higher) risk, according to the International Prognostic Index, who underwent upfront ASCT in first complete remission (CR1). Compared with 10 patients with similar characteristics who did not receive ASCT, event free survival at 5-year was significantly superior in ASCT group. Toxicity of ASCT was acceptable and therapy-related death was not observed. We therefore propose that upfront ASCT for higher risk DLBCL in CR1 might provide survival benefit, probably because the high-dose therapy removes minimally resided tumor.
Keywords: diffuse large B-cell lymphoma; autologous transplantation; upfront diffuse large B-cell lymphoma; autologous transplantation; upfront

Share and Cite

MDPI and ACS Style

Kaneko, H.; Tsutsumi, Y.; Fujino, T.; Kuwahara, S.; Ohshiro, M.; Iwai, T.; Kuroda, J.; Yokota, S.; Horiike, S.; Taniwaki, M. Favorable Event Free-Survival of High-Dose Chemotherapy followed by Autologous Hematopoietic Stem Cell Transplantation for Higher Risk Diffuse Large B-Cell Lymphoma in First Complete Remission. Hematol. Rep. 2015, 7, 5812. https://doi.org/10.4081/hr.2015.5812

AMA Style

Kaneko H, Tsutsumi Y, Fujino T, Kuwahara S, Ohshiro M, Iwai T, Kuroda J, Yokota S, Horiike S, Taniwaki M. Favorable Event Free-Survival of High-Dose Chemotherapy followed by Autologous Hematopoietic Stem Cell Transplantation for Higher Risk Diffuse Large B-Cell Lymphoma in First Complete Remission. Hematology Reports. 2015; 7(2):5812. https://doi.org/10.4081/hr.2015.5812

Chicago/Turabian Style

Kaneko, Hiroto, Yasuhiko Tsutsumi, Takahiro Fujino, Saeko Kuwahara, Muneo Ohshiro, Toshiki Iwai, Junya Kuroda, Shouhei Yokota, Shigeo Horiike, and Masafumi Taniwaki. 2015. "Favorable Event Free-Survival of High-Dose Chemotherapy followed by Autologous Hematopoietic Stem Cell Transplantation for Higher Risk Diffuse Large B-Cell Lymphoma in First Complete Remission" Hematology Reports 7, no. 2: 5812. https://doi.org/10.4081/hr.2015.5812

APA Style

Kaneko, H., Tsutsumi, Y., Fujino, T., Kuwahara, S., Ohshiro, M., Iwai, T., Kuroda, J., Yokota, S., Horiike, S., & Taniwaki, M. (2015). Favorable Event Free-Survival of High-Dose Chemotherapy followed by Autologous Hematopoietic Stem Cell Transplantation for Higher Risk Diffuse Large B-Cell Lymphoma in First Complete Remission. Hematology Reports, 7(2), 5812. https://doi.org/10.4081/hr.2015.5812

Article Metrics

Back to TopTop